M. Dehlinger

发表

Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251

A. Wu, G. Robbins, T. Flynn, 2016, HIV clinical trials.

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen

A. Collier, M. Fischl, P. Tebas, 2007, AIDS.

Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South Africa

R. Wood, C. Orrell, M. Dehlinger, 2010, AIDS.

In vivo additive antiretroviral effect of combined zidovudine and foscarnet therapy for human immunodeficiency virus infection (ACTG Protocol 053).

M. Dehlinger, R. Hafner, J. Mills, 1991, The Journal of infectious diseases.

Nurse management is not inferior to doctor management of antiretroviral patients: The CIPRA South Africa randomised trial

R. Wood, C. Orrell, M. Dehlinger, 2011 .

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

S. Hammer, D. Katzenstein, S. Liou, 2001, The New England journal of medicine.

Pharmacogenomics of HIV Therapy: Summary of a Workshop Sponsored by the National Institute of Allergy and Infectious Diseases

R. Haubrich, J. Fellay, A. Telenti, 2011, HIV clinical trials.

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial

M. Kozal, K. H. Hullsiek, M. Dehlinger, 2006, The Lancet.

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

S. Hammer, M. Saag, A. Collier, 2003, The Journal of infectious diseases.

Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial

R. Wood, C. Orrell, M. Dehlinger, 2010, The Lancet.

Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial.

C. Flexner, R. Gross, J. Aberg, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficacy and Safety of Abacavir Plus Lamivudine Versus Didanosine Plus Stavudine When Combined with a Protease Inhibitor, a Nonnucleoside Reverse Transcriptase Inhibitor, or Both in HIV-1 Positive Antiretroviral-Naive Persons

M. Kozal, M. Dehlinger, M. van den Berg-Wolf, 2004, HIV clinical trials.

P63 Design of a randomized trial of combined nucleoside analog antiretroviral therapy in AIDS patients

T. Church, L. Saravolatz, D. Winslow, 1993 .